Acadia Pharmaceuticals | ACAD - Los Gastos De Explotación

Precio De Mercado
22.44
Cambio Diario
0.24 1.08%
Mensual
0.81%
Anual
54.02%
Q2 Expectativa
21.49




Los Gastos De Explotación Cambio Fecha
Acadia Pharmaceuticals USD 266.6M 23.72M 2025-12
ALKERMES USD 326.44M 1.41B 2025-12
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
Biogen USD 1.96B 69.6M 2026-03
BioMarin Pharmaceutical USD 676.18M 131.65M 2025-12
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Cara Therapeutics USD 5.94M 983K 2025-09
Corcept Therapeutics USD 197.64M 219K 2025-12
Cytokinetics USD 196.12M 27.43M 2025-12
Eisai JPY 199.9B 16.22B 2025-12
Eli Lilly USD 10.02B 285M 2026-03
Incyte USD 5.62B 4.5B 2026-03
J&J USD 17.44B 1.53B 2026-03
Moderna USD 1.54B 259M 2025-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
Prothena USD 27.23M 14.95M 2025-12
PTC Therapeutics USD 246.3M 38.78M 2025-12
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
Vanda Pharmaceuticals USD 466M 20.33M 2025-09
Vertex Pharmaceuticals USD 1.93B 89.1M 2025-12